Trial Profile
A phase II study to assess efficacy of combined treatment with erlotinib (Tarceva) and silybin-phytosome (Siliphos) in patients with epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Silibinin (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Sponsors MedicalLogic
- 04 Jul 2014 New trial record